KR102707502B1 - Apj 효능제로서의 2,4-디히드록시-니코틴아미드 - Google Patents
Apj 효능제로서의 2,4-디히드록시-니코틴아미드 Download PDFInfo
- Publication number
- KR102707502B1 KR102707502B1 KR1020187013119A KR20187013119A KR102707502B1 KR 102707502 B1 KR102707502 B1 KR 102707502B1 KR 1020187013119 A KR1020187013119 A KR 1020187013119A KR 20187013119 A KR20187013119 A KR 20187013119A KR 102707502 B1 KR102707502 B1 KR 102707502B1
- Authority
- KR
- South Korea
- Prior art keywords
- carbonyl
- dimethoxyphenyl
- pyridine
- butyl
- diol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241367P | 2015-10-14 | 2015-10-14 | |
| US62/241,367 | 2015-10-14 | ||
| US201562270659P | 2015-12-22 | 2015-12-22 | |
| US62/270,659 | 2015-12-22 | ||
| PCT/US2016/056769 WO2017066402A1 (en) | 2015-10-14 | 2016-10-13 | 2,4-dihydroxy-nicotinamides as apj agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180067599A KR20180067599A (ko) | 2018-06-20 |
| KR102707502B1 true KR102707502B1 (ko) | 2024-09-13 |
Family
ID=57178558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187013119A Active KR102707502B1 (ko) | 2015-10-14 | 2016-10-13 | Apj 효능제로서의 2,4-디히드록시-니코틴아미드 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10392347B2 (enExample) |
| EP (1) | EP3362442B1 (enExample) |
| JP (1) | JP6837482B2 (enExample) |
| KR (1) | KR102707502B1 (enExample) |
| CN (1) | CN108368087B (enExample) |
| AU (1) | AU2016340264B2 (enExample) |
| BR (1) | BR112018007395A2 (enExample) |
| CA (1) | CA3001974A1 (enExample) |
| CL (1) | CL2018000953A1 (enExample) |
| CO (1) | CO2018004968A2 (enExample) |
| EA (1) | EA034857B1 (enExample) |
| ES (1) | ES2774945T3 (enExample) |
| IL (1) | IL258577B (enExample) |
| MX (1) | MX376824B (enExample) |
| PE (1) | PE20181197A1 (enExample) |
| SG (1) | SG10201908839QA (enExample) |
| TW (1) | TW201720796A (enExample) |
| UY (1) | UY36949A (enExample) |
| WO (1) | WO2017066402A1 (enExample) |
| ZA (1) | ZA201802451B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016263564B2 (en) | 2015-05-20 | 2019-12-05 | Amgen Inc. | Triazole agonists of the APJ receptor |
| CA2988147C (en) | 2015-06-03 | 2023-06-13 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| BR112018010720A8 (pt) | 2015-12-04 | 2019-02-26 | Bristol Myers Squibb Co | agonistas do receptor de apelina e métodos de uso |
| ES2854733T3 (es) | 2015-12-16 | 2021-09-22 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor APJ |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
| ES2844184T3 (es) * | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| CN110072850B (zh) * | 2016-10-14 | 2023-07-21 | 百时美施贵宝公司 | 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂 |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
| MA52487A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Pyrimidinones substituées en tant qu'agonistes du récepteur apj |
| WO2025153720A1 (en) * | 2024-01-19 | 2025-07-24 | Scenic Biotech Bv | Pla2g15 inhibitors |
| WO2026077457A1 (zh) * | 2024-10-12 | 2026-04-16 | 珠海联邦制药股份有限公司 | 一种apj受体激动剂类化合物的制备及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH602664A5 (en) | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
| ZA835878B (en) * | 1982-08-23 | 1985-03-27 | Warner Lambert Co | Cardiotonic agents |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| DE4425616A1 (de) * | 1994-07-20 | 1996-01-25 | Basf Ag | Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung |
| BR9711098B1 (pt) | 1996-07-01 | 2011-10-04 | compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas. | |
| EP1301490A2 (en) | 2000-07-18 | 2003-04-16 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| EP1503993A4 (en) | 2002-05-09 | 2006-05-03 | Cytokinetics Inc | COMPOUNDS, METHODS AND COMPOSITIONS |
| AU2003231799A1 (en) | 2002-05-23 | 2003-12-12 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| WO2005041888A2 (en) | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| EP1697331A4 (en) | 2003-12-19 | 2010-08-04 | Merck Sharp & Dohme | INHIBITORS OF MITOTIC KINESINE |
| US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007037543A1 (ja) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | ビアリールアミド誘導体 |
| CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| EP2016056A4 (en) | 2006-04-21 | 2010-11-10 | Univ Boston | IONIC VISCOELASTIC AND VISCOELASTIC SALTS |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| PL2079707T3 (pl) | 2006-10-10 | 2015-05-29 | Proionic Gmbh | Sposób wymiany 1,3-hetero-aromatycznych 2-karboksylanów z wodą |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| US20110253929A1 (en) | 2008-12-22 | 2011-10-20 | Basf Se | Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
| SG195086A1 (en) | 2011-05-31 | 2013-12-30 | Merck Patent Gmbh | Compounds containing hydrido-tricyano-borate anions |
| AU2012265220A1 (en) | 2011-05-31 | 2014-01-16 | Merck Patent Gmbh | Electrolyte formulations |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| ES2623528T3 (es) * | 2012-09-21 | 2017-07-11 | Sanofi | Derivados de amida de ácido benzoimidazolcarboxílico para tratar enfermedades metabólicas o cardiovasculares |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| CN105324376B (zh) | 2013-06-27 | 2017-06-23 | 辉瑞大药厂 | 杂芳族化合物及其作为多巴胺d1配体的用途 |
| ES2906062T3 (es) | 2013-11-29 | 2022-04-13 | Proionic Gmbh | Procedimiento para la unión de un material termoplástico por medio de radiación de microondas |
| WO2015184011A2 (en) | 2014-05-28 | 2015-12-03 | Sanford-Burnham Medical Research Institute | Agonists of the apelin receptor and methods of use thereof |
| PE20170664A1 (es) * | 2014-06-06 | 2017-06-10 | Res Triangle Inst | Agonistas del receptor de apelina(apj) y usos de los mismos |
| WO2016074757A1 (de) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren |
| EP3287443B1 (en) | 2015-04-24 | 2021-10-27 | Shionogi & Co., Ltd | 6-membered heterocyclic derivative and pharmaceutical composition comprising same |
| AU2016263564B2 (en) | 2015-05-20 | 2019-12-05 | Amgen Inc. | Triazole agonists of the APJ receptor |
| CA2988147C (en) | 2015-06-03 | 2023-06-13 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| KR101711744B1 (ko) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층 |
| EP3380970B1 (en) | 2015-11-24 | 2023-01-04 | Sanford Burnham Prebys Medical Discovery Institute | Novel azole derivatives as apelin receptor agonist |
| BR112018010720A8 (pt) | 2015-12-04 | 2019-02-26 | Bristol Myers Squibb Co | agonistas do receptor de apelina e métodos de uso |
| ES2854733T3 (es) | 2015-12-16 | 2021-09-22 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor APJ |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| ES2844184T3 (es) | 2016-06-14 | 2021-07-21 | Bristol Myers Squibb Co | 4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ |
| CN110072850B (zh) | 2016-10-14 | 2023-07-21 | 百时美施贵宝公司 | 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂 |
-
2016
- 2016-10-13 PE PE2018000536A patent/PE20181197A1/es unknown
- 2016-10-13 TW TW105133123A patent/TW201720796A/zh unknown
- 2016-10-13 JP JP2018519425A patent/JP6837482B2/ja active Active
- 2016-10-13 EP EP16784732.6A patent/EP3362442B1/en active Active
- 2016-10-13 EA EA201890858A patent/EA034857B1/ru not_active IP Right Cessation
- 2016-10-13 BR BR112018007395A patent/BR112018007395A2/pt not_active IP Right Cessation
- 2016-10-13 SG SG10201908839Q patent/SG10201908839QA/en unknown
- 2016-10-13 WO PCT/US2016/056769 patent/WO2017066402A1/en not_active Ceased
- 2016-10-13 UY UY0001036949A patent/UY36949A/es unknown
- 2016-10-13 KR KR1020187013119A patent/KR102707502B1/ko active Active
- 2016-10-13 AU AU2016340264A patent/AU2016340264B2/en not_active Ceased
- 2016-10-13 CA CA3001974A patent/CA3001974A1/en not_active Abandoned
- 2016-10-13 US US15/767,364 patent/US10392347B2/en active Active
- 2016-10-13 CN CN201680072835.5A patent/CN108368087B/zh active Active
- 2016-10-13 MX MX2018004344A patent/MX376824B/es active IP Right Grant
- 2016-10-13 ES ES16784732T patent/ES2774945T3/es active Active
-
2018
- 2018-04-09 IL IL258577A patent/IL258577B/en active IP Right Grant
- 2018-04-13 ZA ZA2018/02451A patent/ZA201802451B/en unknown
- 2018-04-13 CL CL2018000953A patent/CL2018000953A1/es unknown
- 2018-05-10 CO CONC2018/0004968A patent/CO2018004968A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016340264A1 (en) | 2018-05-31 |
| EA034857B1 (ru) | 2020-03-30 |
| US20180297954A1 (en) | 2018-10-18 |
| IL258577B (en) | 2020-07-30 |
| AU2016340264B2 (en) | 2021-01-07 |
| EP3362442B1 (en) | 2020-01-29 |
| SG10201908839QA (en) | 2019-10-30 |
| JP6837482B2 (ja) | 2021-03-03 |
| CO2018004968A2 (es) | 2018-10-10 |
| MX376824B (es) | 2025-03-07 |
| EP3362442A1 (en) | 2018-08-22 |
| US10392347B2 (en) | 2019-08-27 |
| BR112018007395A2 (pt) | 2018-10-23 |
| CN108368087B (zh) | 2022-04-12 |
| CA3001974A1 (en) | 2017-04-20 |
| MX2018004344A (es) | 2018-05-01 |
| JP2018530591A (ja) | 2018-10-18 |
| CN108368087A (zh) | 2018-08-03 |
| ES2774945T3 (es) | 2020-07-23 |
| UY36949A (es) | 2017-04-28 |
| KR20180067599A (ko) | 2018-06-20 |
| PE20181197A1 (es) | 2018-07-23 |
| IL258577A (en) | 2018-05-31 |
| EA201890858A1 (ru) | 2018-09-28 |
| WO2017066402A1 (en) | 2017-04-20 |
| TW201720796A (zh) | 2017-06-16 |
| ZA201802451B (en) | 2020-01-29 |
| CL2018000953A1 (es) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6837482B2 (ja) | Ａｐｊアゴニストとしての２，４−ジヒドロキシ−ニコチンアミド | |
| KR102433280B1 (ko) | Apj 효능제로서의 6-히드록시-4-옥소-1,4-디히드로피리미딘-5-카르복스아미드 | |
| KR102384668B1 (ko) | Apj 효능제로서의 6-히드록시-5-(페닐/헤테로아릴술포닐)피리미딘-4(1h)-온 | |
| KR102678264B1 (ko) | 아펠린 수용체 효능제 및 사용 방법 | |
| KR102742744B1 (ko) | Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논 | |
| KR102066336B1 (ko) | 심혈관 장애의 치료에 사용하기 위한 4-히드록시-3-(헤테로아릴)피리딘-2-온 apj 효능제 | |
| KR102521955B1 (ko) | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 | |
| KR102521956B1 (ko) | 3-술포닐-5-아미노피리딘-2,4-디올 apj 효능제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180509 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211012 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20231020 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240612 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240911 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240911 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |